2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1919

Development of a Multi-Modality Imaging Approach to Evaluate Lupus Nephritis
Abstract Number: 1920

School Nurse Education for Juvenile Idiopathic Arthritis
Abstract Number: 1921

Parent-Reported Medication Side-Effects and Their Impact on Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Abstract Number: 1922

Improvement in Hepatitis B Screening Prior to Initiation of Biologic Therapy in the Pediatric Rheumatology Clinic
Abstract Number: 1923

Disability and Health-Related Quality of Life Outcomes in Patients with Systemic or Polyarticular Juvenile Idiopathic Arthritis Treated with Tocilizumab in Randomized Controlled Phase 3 Trials
Abstract Number: 1924

Assessing Psychosocial Needs in Juvenile Dermatomyositis Patients Across the United Kingdom
Abstract Number: 1925

Discriminant and Predictive Ability of the Parent Version of the Juvenile Arthritis Disease Activity Score in Two Large Multination Cohorts of Patients with Juvenile Idiopathic Arthritis
Abstract Number: 1926

Characterization of DOCK8 as a Novel Gene Associated with Macrophage Activation Syndrome
Abstract Number: 1927

Role of Mitochondrial DNA from OA Patients in Cellular Apoptosis, Senescence and Autophagy
Abstract Number: 1928

Identification of Immunological Processes Associated with the Response to Abatacept in Rheumatoid Arthritis Using Longitudinal Blood RNA-seq Analysis
Abstract Number: 1929

Identification and Validation of Transcriptional Genes Associated with Osteoporotic Vertebral Fractures by Microarray Study, in Community Elderly Women
Abstract Number: 1930

Analysis of Lupus Nephritis Gene Expression Reveals Dysregulation of Pathogenic Pathways Activated Within Infiltrating Cells
Abstract Number: 1931

Comprehensive Characterization of the Immune Infiltrate of Skin Biopsies from Cutaneous Lupus Erythematosus Patients Using Single Cell RNAseq
Abstract Number: 1932

Genetic Evidence for Recent Positive Selection of the HLA-B*51:01 Allele in the Turkish Population, a Population with a High Prevalence of HLA-B*51-Associated Behçet’s Disease
Abstract Number: 1933

Tumorigenesis Related Gene Identification in Dermatomyositis Using Meta-Analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].